Actinium Pharmaceuticals (NYSE:ATNM) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Actinium Pharmaceuticals (NYSE:ATNM) posted its quarterly earnings data on Monday. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02, Yahoo Finance reports.

Actinium Pharmaceuticals Stock Performance

ATNM traded down $0.27 during trading on Wednesday, reaching $2.60. 663,087 shares of the company were exchanged, compared to its average volume of 465,251. Actinium Pharmaceuticals has a 12-month low of $1.33 and a 12-month high of $10.24. The stock has a market capitalization of $77.44 million, a price-to-earnings ratio of -1.54 and a beta of 0.20.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ATNM shares. Maxim Group lowered their price target on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday. Stephens began coverage on Actinium Pharmaceuticals in a research report on Tuesday, May 14th. They set an “overweight” rating and a $25.00 price target on the stock. HC Wainwright decreased their price objective on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price objective on shares of Actinium Pharmaceuticals in a report on Tuesday, April 30th. Finally, StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $13.77.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.